These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15809102)

  • 1. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors.
    Eisen H; Kobashigawa J; Starling RC; Valantine H; Mancini D
    Transplant Proc; 2005 May; 37(4 Suppl):4S-17S. PubMed ID: 15809102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H; Zuckermann A
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
    Viganò M; Tuzcu M; Benza R; Boissonnat P; Haverich A; Hill J; Laufer G; Love R; Parameshwar J; Pulpón LA; Renlund D; Abeywickrama K; Cretin N; Starling RC; Eisen HJ;
    J Heart Lung Transplant; 2007 Jun; 26(6):584-92. PubMed ID: 17543781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferation signal inhibitors and cardiac allograft vasculopathy.
    Raichlin E; Kushwaha SS
    Curr Opin Organ Transplant; 2008 Oct; 13(5):543-50. PubMed ID: 19060540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
    Lehmkuhl H; Hetzer R
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
    Zuckermann A
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation.
    Delgado JF; Manito N; Segovia J; Almenar L; Arizón JM; Campreciós M; Crespo-Leiro MG; Díaz B; González-Vílchez F; Mirabet S; Palomo J; Roig E; de la Torre JM
    Transplant Rev (Orlando); 2009 Apr; 23(2):69-79. PubMed ID: 19298938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation.
    Eisen H
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii9-13. PubMed ID: 16815858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure.
    Lehmkuhl H; Ross H; Eisen H; Valantine H
    Transplant Proc; 2005 Dec; 37(10):4145-9. PubMed ID: 16387066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
    J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now?
    Zuckermann A; Wang SS; Epailly E; Barten MJ; Sigurdardottir V; Segovia J; Varnous S; Turazza FM; Potena L; Lehmkuhl HB
    Transplant Rev (Orlando); 2013 Jul; 27(3):76-84. PubMed ID: 23643624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical recommendations for the use of everolimus in heart transplantation.
    Manito N; Delgado JF; Crespo-Leiro MG; González-Vílchez F; Almenar L; Arizón JM; Díaz B; Fernández-Yáñez J; Mirabet S; Palomo J; Rodríguez Lambert JL; Roig E; Segovia J
    Transplant Rev (Orlando); 2010 Jul; 24(3):129-42. PubMed ID: 20619801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting.
    Bocchi EA; Ahualli L; Amuchastegui M; Boullon F; Cerutti B; Colque R; Fernandez D; Fiorelli A; Olaya P; Vulcado N; Perrone SV
    Transplant Proc; 2006 Apr; 38(3):937-42. PubMed ID: 16647515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
    González-Vílchez F; de Prada JA; Exposito V; García-Camarero T; Fernández-Friera L; Llano M; Ruano J; Martín-Durán R
    J Heart Lung Transplant; 2008 Oct; 27(10):1135-41. PubMed ID: 18926406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.
    Chapman JR; Valantine H; Albanell J; Arns WA; Campistol JM; Eisen H; Frigerio M; Lehmkuhl H; Marcen R; Morris R; Nashan B; Pascual J; Pohanka E; Segovia J; Zuckermann A
    Transplant Proc; 2007 Dec; 39(10):2937-50. PubMed ID: 18089298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.
    Valantine H
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS; Khalpey Z; Frantz RP; Rodeheffer RJ; Clavell AL; Daly RC; McGregor CG; Edwards BS
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.